The FDA decision on Insys Therapeutics Inc.’s (INSY) Syndros as a treatment for anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy is scheduled for July 1, 2016. Syndros is a proprietary orally administered liquid formulation of pharmaceutical cannabinoid dronabinol, a synthetic version of tetrahydrocannabinol that is believed to have distinct advantages over the current formulation of dronabinol in soft gel capsules, marketed as Marinol by privately-held Unimed Pharmaceuticals LLC. Insys also markets a generic equivalent to Marinol.In October 2014, the FDA refused to review Syndros NDA as the application was not sufficiently complete – with an inadequate or incomplete pediatric study plan to conduct studies to assess the safety and effectiveness of Dronabinol Oral Solution in pediatric patients.If approved, the company expects peak sales potential of Syndros in excess of $200 million.